

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.: 10/541,522

Confirmation No.: Unknown

Applicant: Brown *et al.*

PCT Appl. No.: PCT/GB2004/000099

National Phase Fld (371): July 7, 2005

PCT Filed: January 13, 2004

Docket No.: 100952-1P US

TC/A.U.: Unknown

Customer No.: 22466

Examiner: Unknown

Title: Diarylmethylidene Piperidine Derivatives, Preparations Thereof and Uses Thereof

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit herewith a list of patents and publications for which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO/SB/08A and 08B forms.


Applicants also wish to make the Examiner aware of co-pending applications:

10/477851, a PCT national phase filed on May 16, 2002;
10/477854, a PCT national phase filed on May 16, 2002;
10/477641, a PCT national phase filed on May 16, 2002;
10/477821, a PCT national phase filed on May 16, 2002;
10/240114, a PCT national phase filed on March 30, 2001;
10/240038, a PCT national phase filed on March 30, 2001;
10/222990, filed on August 19, 2002;
10/541664, a PCT national phase filed on January 13, 2004; and
10/541656, a PCT national phase filed on January 13, 2004.

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

This Information Disclosure Statement is being filed before the mailing date of a first office action on the merits and therefore, pursuant to 37 C.F.R. § 1.97(b), no fee is required pursuant to 37 C.F.R. § 1.17(p).

Respectfully submitted,



Jianzhong Shen
Reg. No.48,076
302-886-8854

Dated: October 17, 2005

Enclosures: Transmittal Form
Forms PTO/SB/08A & 08B
References (13)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/541,522
Sheet 1 of 3		Filing Date	July 7, 2005
		First Named Inventor	William Brown
		Art Unit	Unknown
		Examiner Name	Unknown
		Attorney Docket Number	100952-1P US

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 2,898,339	08/04/1959	Wheeler et al.	
		US- 4,581,171	04/08/1986	Kennis et al.	
		US- 4,816,586	03/28/1989	Portoghesi	
		US- 4,939,137	07/03/1990	Russell et al.	
		US- 5,140,029	08/18/1992	Kennis et al.	
		US- 5,574,159	11/12/1996	Chang et al.	
		US- 5,683,998	11/04/1997	Shibayama et al.	
		US- 6,187,792	02/13/2001	Delorme et al.	
		US- 6,455,545	09/24/2002	Delorme et al.	
		US- 6,552,036	04/22/2003	Boyd et al.	
		US- 6,556,387	04/29/2003	Misso et al.	
		US- 6,756,387	06/29/2004	Brown et al.	
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		WO 93/15062	08/05/1993	The Wellcome Foundation		
		WO 97/23466	07/03/1997	Astra Aktiebolag		
		WO 98/28275	07/02/1998	Astra Pharma, Inc.		
		WO 99/33806	07/08/1999	Ortho-McNeil Pharmaceutic		
		WO 01/74804	10/11/2001	AstraZeneca AB		
		WO 01/74806	10/11/2001	AstraZeneca AB		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 3

<i>Complete if Known</i>	
Application Number	10/541,522
Filing Date	July 7, 2005
First Named Inventor	William Brown
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	100952-1P US

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
<i>(Use as many sheets as necessary)</i>			
Sheet	3	of	3
		Attorney Docket Number	
		100952-1P US	


NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
		BARBER, A. et al., "Antinociceptive effects of the 5-HT2 Antagonist Ritanserin in Rats: Evidence... in the Spinal Cord," Neuroscience Letters, 1989, Vol. 99, p. 234-238		
		BILSKY, E. et al., "SNC 80, A Selective, Nonpeptidic and Systematically Active Opioid Delta Agonist," J. Pharmacology Experimental Ther., 1995, Vol. 273, p. 359-366		
		GREENE, T., "Protective Groups in Organic Synthesis," Wiley & Sons, 1982, p. 218, 220, 232, 233, 251		
		TAKEMORI, A.E. et al., "Selective Naxetone-Derived Opioid Receptor Antagonists," Annu. Rev. Pharmacol. Toxicol., 1992, Vol. 32, p. 239-269		
		WEI, Z. et al., "N,N-Diethyl-4-(phenylpiperidin-4-ylidene)methyl)benzamide: A Novel...and its Analogues," J. Med. Chem., 2000, Vol. 43, p. 3895-3905		
		ZHANG, X. et al., "Probes for Narcotic Receptor Mediated Phenomena. 26. 1-3 Synthesis... Opioid Receptor Ligands, J. Med. Chem., 1999, Vol. 42, p. 5455-5463		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



JC03 2005 19 OCT 2005 PCT

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/541,522
Filing Date	July 7, 2005
First Named Inventor	Brown
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	100952-1P US

6

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please Identify below):
<input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address	
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Remarks	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name			
Signature			
Printed name	Jianzhong Shen		
Date	October 17, 2005	Reg. No.	48,076

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

Typed or printed name

Liz Ashton

Date October 17, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Application of: BROWN, William et al.
US Application No: Not Yet Assigned
US Application Filed:

PCT Application No: PCT/SE02/01804
PCT Filed: October 2, 2002

For: 4[Piperidin-4-Ylidene-(3-Carbamoylphenyl)Methyl]Benzamide Derivatives and
Their Use for the Treatment of Pain, Spinal Injuries or Gastrointestinal Disorders

Examiner: Not yet allocated
Group Art Unit: Not yet allocated

Mail Stop PCT
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit herewith a list of patents and publications for which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

Applicants also wish to make the Examiner aware of co-pending applications:


100368 10/477851, a PCT national phase filed on May 16, 2002;
100369 10/477854, a PCT national phase filed on May 16, 2002;
100370 10/477641, a PCT national phase filed on May 16, 2002;
100367 10/477821, a PCT national phase filed on May 16, 2002;
100002 10/240114, a PCT national phase filed on March 30, 2001;
100001 10/240038, a PCT national phase filed on March 30, 2001; and
A1570-3 10/222990, filed on August 19, 2002.

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

This Information Disclosure Statement is being filed together with the filing under 35 U.S.C. § 371 of the national stage of an international application and hence no fee is required for consideration of the references. However, the Examiner is authorized to charge any fees that may be due to Deposit Account No. 260166.

Respectfully submitted,

Dated: March 30, 2004



Jianzhong Shen
Agent for Applicants
Reg. No. 48,076
Telephone: 302/886-8854

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete If Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

2

Application Number	Not Yet Assigned
Filing Date	
First Named Inventor	William Brown, et al.
Art Unit	
Examiner Name	Not Yet Assigned
Attorney Docket Number	Not Yet Assigned

100492-1P US

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
A1	US	2,898,339	Aug. 4, 1959	Wheeler, et al.	
A2	US	4,581,171	April 8, 1986	Kennis, et al.	
A3	US	4,816,586	March 28, 1989	Portoghesi	
A4	US	4,939,137	July 3, 1990	Russell, et al.	
A5	US	5,140,029	Aug. 18, 1992	Kennis, et al.	
A6	US	5,574,159	Nov. 12, 1996	Chang, et al.	
A7	US	5,683,998	Nov. 4, 1997	Shibayama, et al.	
A8	US	6,187,792	Feb. 13, 2001	Delorme, et al.	
A9	US	6,455,545	Sept., 24, 2002	Delorme, et al.	
	US-				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
B1	WO	99/33806	July 8, 1999	Ortho-McNeil Pharmaceutical, Inc.		
B2	WO	93/15062	Aug. 5, 1993	The Wellcome Foundation Ltd.		
B3	WO	97/23466	July 3, 1997	Astra Aktiebolag		
B4	WO	98/28275	July 2, 1998	Astra Pharma, Inc.		
B5	WO	0174804	Oct. 11, 2001	AstraZeneca AB		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete If Known

Application Number	Not Yet Assigned
Filing Date	
First Named Inventor	William Brown, et al.
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	100492-1P US

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	B6	WO 0174806	Oct. 11, 2001	AstraZeneca AB		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: In that II reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.² Applicant's unique citation designation number (optional).³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁷ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

Complete If Known	
Application Number	Not Yet Assigned
Filing Date	
First Named Inventor	William Brown et al.
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	100492-1P US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Bilsky, et al., "SNC 80, A Selective, Nonpeptidic and Systemically Active Opioid Delta Agonist, J. Pharmacol. Experi. Ther. 273:359-366(1995)	
	C2	Takemori, et al., "Selective Naltrexone-Driven Opioid Receptor Antagonists," Annu. Rev. Pharmacol. Toxicol. 32:239-269 (1992).	
	C3	Barber, et al., "Antinociceptive Effects of the 5-HT Antagonist Ritanserin in Rats: Evidence for an Activation... in the Spinal Cord," Neuroscience Letters 99:234-238 (1989).	
	C4	Greene, "Protective Groups in Organic Synthesis," Wiley & sons, pp. 218, 220, 232, 233, 251 (1982).	
	C5	Wei, et al., "N,N-Diethyl-4-(phenylpiperidin-4-ylidene)methyl) . . . and its Analogues," J. Med. Chem. 43:3895-3905 (2000).	
	C6	Zhang, et al., "Probes for Narcotic Receptor Mediated Phenomena. 26. 1-3 Synthesis . . . Opioid Receptor Ligands," J. Med. Chem. 42:5455-5463 (1999).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Application of: BROWN, William et al.
US Application No: 10/477821
US Application Filed: November 13, 2003

PCT Application No: PCT/SE02/00953
PCT Filed: May 16, 2002

For: 4-(Phenyl-Piperidin-4-Ylidene-Methyl)-Benzamide
Derivatives and Their use for the Treatment of Pain,
Anxiety or Gastrointestinal Disorders

Examiner: Not yet allocated
Group Art Unit: Not yet allocated

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit herewith a list of patents and publications for which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

Applicants also wish to make the Examiner aware of co-pending applications:


100368 10/477851, a PCT national phase filed on May 16, 2002;
100369 10/477854, a PCT national phase filed on May 16, 2002;
100370 10/477641, a PCT national phase filed on May 16, 2002;
100002 10/240114, a PCT national phase filed on March 30, 2001;
100001 10/240038, a PCT national phase filed on March 30, 2001; and
A1570-3 10/222990, filed on August 19, 2002.

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

This Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits; and hence no fee is required for consideration of the references. However, the Examiner is authorized to charge any fees that may be due to Deposit Account No. 260166.

Respectfully submitted,

Dated: February 18, 2004


Jianzhong Shen
Agent for Applicants
Reg. No. 48,076
Telephone: 302/886-8854

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of 2

Complete if Known

Application Number	10/477821
Filing Date	November 13, 2003
First Named Inventor	William Brown, et al.
Art Unit	
Examiner Name	

Attorney Docket Number 100367-1P US

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
A1	US- 2,898,339 ✓		Aug. 4, 1959	Wheeler, et al.	
A2	US- 4,581,171 ✓		April 8, 1986	Kennis, et al.	
A3	US- 4,816,586 ✓		March 28, 1989	Portoghesi	
A4	US- 4,939,137 ✓		July 3, 1990	Russell, et al.	
A5	US- 5,140,029 ✓		Aug. 18, 1992	Kennis, et al.	
A6	US- 5,574,159 ✓		Nov. 12, 1996	Chang, et al.	
A7	US- 5,683,998 ✓		Nov. 4, 1997	Shibayama, et al.	
A8	US- 6,187,792 ✓		Feb. 13, 2001	Delorme, et al.	
A9	US- 6,455,545 ✓		Sept., 24, 2002	Delorme, et al.	
	US-				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
B1	WO 99/33806 ✓		July 8, 1999	Ortho-McNeil Pharmaceutical, Inc.		
B2	WO 93/15062 ✓		Aug. 5, 1993	The Wellcome Foundation Ltd.		
B3	WO 97/23466 ✓		July 3, 1997	Astra Aktiebolag		
B4	WO 98/28275 ✓		July 2, 1998	Astra Pharma, Inc.		
B5	WO 0174804 ✓		Oct. 11, 2001	AstraZeneca AB		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheaf

1

8

1

Complete if Known

Application Number	10/477821
Filing Date	November 13, 2003
First Named Inventor	William Brown, et al.
Art Unit	
Examiner Name	
Attorney Docket Number	100367-1P LIS

Attorney Docket Number 100367-1P US

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner _____ Date Considered _____

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(Use as many sheets as necessary)					
Sheet	1	of	1		
Attorney Docket Number 100367-1P US					

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
✓	C1	Bilsky, et al., "SNC 80, A Selective, Nonpeptidic and Systemically Active Opioid Delta Agonist, J. Pharmacol. Experi. Ther. 273:359-366(1995)				
✓	C2	Takemori, et al., "Selective Naltrexone-Driven Opioid Receptor Antagonists," Annu. Rev. Pharmacol. Toxicol. 32:239-269 (1992).				
✓	C3	Barber, et al., "Antinociceptive Effects of the 5-HT Antagonist Ritanserin in Rats: Evidence for an Activation... in the Spinal Cord," Neuroscience Letters 99:234-238 (1989).				
✓	C4	Greene, "Protective Groups in Organic Synthesis," Wiley & sons, pp. 218, 220, 232, 233, 251 (1982).				
✓	C5	Wei, et al., "N,N-Diethyl-4-(phenylpiperidin-4-ylidene)methyl) . . . and its Analogues," J. Med. Chem. 43:3895-3905 (2000).				
	C6	Zhang, et al., "Probes for Narcotic Receptor Mediated Phenomena. 26. 1-3 Synthesis . . . Opioid Receptor Ligands," J. Med. Chem. 42:5455-5463 (1999).				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Notice of References Cited		Application/Control No.	Applicant(s)/Patent Under Reexamination	
		10/477,821	WEI ET AL.	
Examiner Rita J. Desai		Art Unit 1825		Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-KinJ Code	Date MM-YYYY	Name	Classification
X	A	US-6,756,387 6,756,387	03-2004	Brown et al. 10-29-04	514/318
X	B	US-6,455,515 6,455,515	09-2002	Delorme et al. 9-24-02 already cited on IDS 614/320	
X	C	US-6,652,036 6,652,036	04-2003	Boyd et al. 4-22-03	514/299
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-KinJ Code	Date MM-YYYY	Country	Name	Classification
X	N	WO00/202715 98/26275	07-1998	WO already cited	Delorme D. et al	---
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
X	U	Wei et al, N,N-diethyl-4-(phenylpiperidine-4-ylidene)methylbenzamide. J. of Med. Chem. 2000, Vol 43, 3895-3905 already cited on IDS
	V	
	W	
	X	

A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Notice of References Cited		Application/Control No.	Applicant(s)/Patent Under Reexamination WEI ET AL.	
		10/477,821	Examiner Rita J. Desai	Art Unit 1625
				Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-6,556,387	04-2003	Misso et al.	360/265.6
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(e).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.